ClinicalTrials.gg
RecruitingNCT04709900DYNAMITEUpdated Nov 5, 2026

CT Stress Myocardial Perfusion, Fractional Flow Reserve and Angiography in Patients With Stable Chest Pain Syndromes

An interventional study of CT angiography, FFR-CT and stress CT myocardial perfusion in Coronary Artery Disease, Chest Syndrome and Acute Myocardial Infarction, sponsored by Copenhagen University Hospital, Rigshospitalet. Recruiting at 1 site in Denmark. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Copenhagen University Hospital, Rigshospitalet · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2021; still recruiting 4 years 11 months later.
Updated Nov 5, 2026Primary completion movedSponsor changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,000
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 184 studies in Coronary Artery Disease with a site in Denmark — 23 open to participants now, 44 under way, 5 of them phase 3. Coronary Artery Disease · Denmark.

Planned enrollment
36th of 136
2,000 · median 455
Started
2021
with 6 others
No phase
88 of 184
16 open now
Primary completion
2026-12
later than 22 of 43 live
Registered
145th of 184
by date

Among the 184 studies in Coronary Artery Disease with a site in Denmark, this one is the 36th largest by planned enrollment of the 136 interventional ones that give a count, is one of 7 that started in 2021, is one of 88 with no phase, reaches primary completion later than 22 of the 43 other live ones, and was the 145th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

23 of the 184 studies in Coronary Artery Disease with a site in Denmark are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 184 studies in Coronary Artery Disease with a site in Denmark, or all of them as a file.
02

Study summary

The purpose of the DYNAMITE trial (Dynamic CT stress myocardial perfusion, CT fractional flow reserve (FFR-CT) and coronary CT angiography for optimized treatment strategy in patients with chest pain syndromes) is to determine the ability of combined anatomical and functional cardiac CT imaging to improve morbidity and mortality in patients with suspected or known ischemic heart disease.

Read the detailed description

Trial design

The DYNAMITE trial is an investigator-initiated, randomised controlled, open-labelled trial conducted in the Capital Region of Copenhagen, Denmark

The following hypothesis will be tested:

  • First primary hypothesis: A treatment strategy guided by combined dynamic CT myocardial stress perfusion, FFR-CT and CT coronary angiography improves clinical outcome compared with a conventional management strategy in patients with chronic chest pain syndromes
  • Second primary hypothesis: A treatment strategy guided by combined dynamic CT stress myocardial perfusion, FFR-CT and CT coronary angiography results in improved symptom relief compared with a conventional management strategy in patients with chronic chest pain syndromes
03

Conditions studied

  • Coronary Artery Disease
  • Chest Syndrome
  • Acute Myocardial Infarction
  • Heart Failure
  • Stroke
  • Cardiovascular Diseases

Keywords

  • Cardiac CT
  • Chest pain
  • Coronary artery disease
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chest pain in patients with clinically suspected or confirmed ischemic heart disease
  • Clinical indication for non-acute coronary evaluation
  • Status of coronary revascularization

    1. With previous coronary revascularization - all patients
    2. Without previous coronary revascularization

      1. Age≥65 years - all patients with chest pain
      2. Age>50 - \<65 years - typical angina pectoris and at least one cardiovascular risk factor and/or previous myocardial infarction

        • Typical angina requiring all 3 criteria present: a) constrictive discomfort in the front of the chest or in the neck, jaw, shoulder or arm, b) precipitated by physical exertion c) relieved by rest or nitrates within 5 min.
        • Cardiovascular risk factors: hypertension, diabetes, hypercholesterolemia, current smoking, family history of ischemic heart disease, previous stroke, peripheral artery disease

Exclusion criteria

Exclusion Criteria:

  • Persistent chest pain and signs of ongoing acute myocardial ischemia requiring acute coronary intervention
  • Hospitalization and discharge with the confirmed diagnosis acute coronary syndrome (STEMI or NSTEMI) within the last 6 months
  • Severe valvular heart disease as primary diagnosis and/or in potential need of percutaneous or surgical valve treatment
  • Known severe heart failure ( less than 35%)
  • Language, cultural or mental factors preventing the patient from understanding the form
  • Known atrial fibrillation
  • Known renal impairment (estimated below \<30 ml/min)
  • Known x-ray contrast allergy
  • Known intolerance to adenosine infusion
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,000 participants (estimated)

Study arms

  • Active comparator
    Intervention group

    CT angiography, FFR-CT and dynamic CT stress myocardial perfusion guided treatment strategy

    Diagnostic Test: CT angiography, FFR-CT and stress CT myocardial perfusion

  • No intervention
    Standard care group

    Evaluation and treatment strategy according to contemporary clinical practice

Interventions

  • Diagnostic testCT angiography, FFR-CT and stress CT myocardial perfusion

    The study intervention team consists of a specialist in Cardiac CT imaging, an invasive cardiologist, a thoracic surgeon and a cardiology nurse specialist. Treatment strategy defined by the study team based on CT findings involve referral for percutaneous coronary intervention, Coronary Artery Bypass surgery and/or initiation of optimal medical therapy, in addition to potential supplementary diagnostic procedures.

06

What researchers measure

Primary outcomes

  1. Major Adverse Cardiovascular Events

    cardiovascular death, acute myocardial infarction, stroke or hospitalization for heart failure

    Time frame: 3 years

Secondary outcomes

  1. Individual components of the primary endpoint

    cardiovascular death; acute myocardial infarction; stroke or hospitalization for heart failure

    Time frame: 3 years

  2. Acute myocardial infarction stratified by subtype

    Subtypes of acute myocardial infarction according to Fourth Universal Definition 2018

    Time frame: 12 months

  3. Hospitalization due to unstable angina pectoris, bleeding, pacemaker and/or implantable/cardioverter defibrillator implantation, surgical or percutaneous heart valve treatment

    Cardiovascular hospitalizations

    Time frame: 3 years

  4. All-cause mortality

    All-cause mortality

    Time frame: 3 years

  5. All-cause mortality

    Long-term registry based all-cause mortality at 10 years

    Time frame: 10 years

  6. Number and type of diagnostic tests performed

    Cardiac CT, Exercise ECG, perfusion Positron Emission Tomography, perfusion Single-photon emission computed tomography, perfusion magnetic resonance, invasive coronary angiography, invasive fractional flow reserve, intravascular ultrasound, optical coherence tomography

    Time frame: 12 months

  7. Number of invasive coronary test not leading to coronary revascularization

    number of invasive procedures

    Time frame: 12 months

  8. Number of coronary revascularization

    Coronary bypass surgery and/or percutaneous coronary intervention

    Time frame: 3 years

  9. Cumulative iodinated contrast volume

    Cardiac computed tomography, invasive coronary angiography, invasive fractional flow reserve, intravascular ultrasound, invasive optical coherence tomography

    Time frame: 12 months

  10. Cumulative radiation dose

    Cardiac CT, perfusion Positron Emission Tomography, perfusion Single-photon emission computed tomography, perfusion magnetic resonance, invasive coronary angiography, invasive fractional flow reserve, intravascular ultrasound, optical coherence tomography

    Time frame: 12 months

  11. Major procedural complications occuring during procedures (invasive, non-invasive or coronary revascularization)

    death, cardiac arrest, cardiac arrhytmia, acute myocardial infarction, stroke, bleeding, unplanned revascularization and any complication requiring and/or prolonging hospitalizaation at least 24 hours

    Time frame: 12 months

  12. Minor procedural complication specific to type of procedure (invasive, non-invasive or during coronary revascularization)

    Minor procedural complications

    Time frame: 12 months

  13. Patients diagnosed with non-cardiac disease as likely explanation for symptoms

    non-cardiac diseases causing chest pain

    Time frame: 12 months

  14. Seattle Angina Questionaire

    Seattle Angina Questionaire pre-randomization, 3 months and 12 months after randomization

    Time frame: 3 months and 12 months

  15. Quality of life by EQ-5D-5L instrument

    Quality of life estimated by EQ-5D-5L instrument pre-randomization, 3 months and 12 months after randomization

    Time frame: 3 months and 12 months

07

Study locations

1 of 1 sites recruiting
  • Department of Cardiology and Radiology, Rigshospitalet, The Heart Center, Capital Region of Copenhagen, University of Copenhagen
    Copenhagen, 2100, Denmark
    Recruiting
    • Klaus F Kofoed, MD, DmSc · ContactKlaus.kofoed@regionh.dk · +45 35458569
    • Jesper J Linde, MD, Ph.D · Sub investigator
    • Lars V Køber, MD,DmSc · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — Following publication of the main results of the trial, anonymized data will be made available to other researchers through the Zenodo open data repository.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Statistical Analysis Plan and study protocol a time of publication

Access criteria: Curated by principle investigator according to contemporary law

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2021 (actual). Primary completion is estimated for Dec 2026, 60 months after the start.

Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 60 months is above that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

Primary completion moved once since we started tracking on Sep 25, 2026: Dec 2024 → Dec 2026, on Nov 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2021
First posted
Jan 14, 2021
StartActual
Dec 3, 2021
Primary completionEst.
Dec 2026was Dec 2024
CompletionEst.
Dec 2031
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 2024→Dec 2026
Nov 5, 2026
Sponsor
Rigshospitalet, Denmark→Copenhagen University Hospital, Rigshospitalet
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Primary completion Dec 2024→Dec 2026
    Sponsor Rigshospitalet, Denmark→Copenhagen University Hospital, Rigshospitalet
    + 3 other changes: identifiers, verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04709900
Lead sponsor
Copenhagen University Hospital, Rigshospitalet
Responsible party
Klaus Fuglsang Kofoed (Clinical associated Research Professor, Copenhagen University Hospital, Rigshospitalet) — Principal investigator
First posted
Jan 14, 2021
Start date
Dec 3, 2021
Primary completion
Dec 2026 (estimated)
Completion
Dec 2031 (estimated)
Last update
Nov 5, 2026

Study contacts

Klaus F Kofoed, MD
Contact
Klaus.kofoed@regionh.dk
004535458569
Klaus F Kofoed, MD
principal investigator · Department of Cardiology, Rigshospitalet, University of Copenhagen, Denmark

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion